A randomized, placebo-controlled phase ii study evaluating the reduction of neutropenia and febrile neutropenia in patients with colorectal cancer receiving pegfilgrastim with every-2-week chemotherapy. [electronic resource]
Producer: 20100817Description: 95-101 p. digitalISSN:- 1938-0674
- Adenocarcinoma -- drug therapy
- Adolescent
- Adult
- Aged
- Aged, 80 and over
- Antineoplastic Combined Chemotherapy Protocols -- administration & dosage
- California
- Camptothecin -- administration & dosage
- Colorectal Neoplasms -- drug therapy
- Confidence Intervals
- Disease Progression
- Double-Blind Method
- Female
- Fever
- Filgrastim
- Fluorouracil -- administration & dosage
- Granulocyte Colony-Stimulating Factor -- therapeutic use
- Humans
- Incidence
- Kaplan-Meier Estimate
- Leucovorin -- administration & dosage
- Male
- Middle Aged
- Neutropenia -- chemically induced
- Odds Ratio
- Organoplatinum Compounds -- administration & dosage
- Polyethylene Glycols
- Recombinant Proteins
- Risk Factors
- Young Adult
No physical items for this record
Publication Type: Clinical Trial, Phase II; Journal Article; Randomized Controlled Trial; Research Support, Non-U.S. Gov't
There are no comments on this title.
Log in to your account to post a comment.